TNM Staging on a — PET-CT Report

The number describes the degree of involvement in each category. For T, higher numbers mean a larger tumour or one that has grown further into surrounding tissue — T1 is typically small and contained, T4 has usually grown into nearby structures. For N, 0 means no nodal involvement was seen, while 1, 2 or 3 describe increasing degrees of nodal spread. For M, only 0 (no distant spread detected) and 1 (distant spread found) are used in most systems. The exact definitions for each number are cancer-type specific — the same T2 in lung cancer and T2 in bowel cancer describe different things.

PET shows metabolic activity — which areas are absorbing the radioactive tracer — while CT shows anatomy and structure. Together, they allow the radiologist to see both where something is and whether it is metabolically active. This can identify nodal or distant spread that looks unremarkable on CT but shows increased tracer uptake on PET, or confirm that an enlarged node on CT is not metabolically active and therefore less likely to be involved. The combination generally gives a more complete picture, which is why it is used for staging many cancers.

The small letter before TNM tells you how the stage was established. cTNM is the clinical stage — an estimate from scans, examination and any pre-surgical biopsies. pTNM is the pathological stage — assigned after surgery, from tissue examined under a microscope in a laboratory. pTNM is generally more precise because it can detect microscopic spread that no scan can see. If you have not had surgery, your report will use cTNM. After surgery, the pathology report will include pTNM, and the two may differ.

M1 means the scan found evidence of cancer at a distant site — somewhere beyond the primary tumour and its nearby lymph nodes. It does not mean a particular treatment is ruled out. For some cancers and some patients, M1 disease is treated with systemic therapy aimed at controlling spread. For others, treatment of the primary site and individual metastatic sites may be possible. What M1 means for your plan depends on your cancer type, how many distant sites are involved, where they are, and your overall fitness. Ask your oncologist which sites were described and what approach they recommend.

Yes. PET-CT is sensitive but not perfect. Very small deposits may not produce enough tracer uptake to appear on the scan. Some cancers are also not FDG-avid, meaning they absorb the tracer poorly regardless of size. This is why the imaging stage is an estimate rather than a certainty. If your oncologist suspects a specific area, they may recommend a biopsy or a different type of scan to assess it more precisely. A clear PET-CT means no spread was detectable with this method — it cannot confirm that every last deposit has been found.

Ask four things: what the individual T, N and M values mean for your cancer type specifically; what overall stage group they correspond to; whether this is a clinical or pathological stage; and whether the stage is expected to change after any planned surgery or biopsy. If any value has an X after it — Tx, Nx or Mx — ask why that component could not be assessed and whether further testing is planned. Writing these questions down before the appointment helps, because staging conversations can cover a lot of ground quickly.